RT Journal Article
T1 Ampicillin Plus Ceftriaxone Combined Therapy for Enterococcus faecalis Infective Endocarditis in OPAT.
A1 Herrera-Hidalgo, Laura
A1 Lomas-Cabezas, Jose Manuel
A1 Lopez-Cortes, Luis Eduardo
A1 Luque-Marquez, Rafael
A1 Lopez-Cortes, Luis Fernando
A1 Martinez-Marcos, Francisco J
A1 de-la-Torre-Lima, Javier
A1 Plata-Ciezar, Antonio
A1 Hidalgo-Tenorio, Carmen
A1 Garcia-Lopez, Maria Victoria
A1 Vinuesa, David
A1 Gutierrez-Valencia, Alicia
A1 Gil-Navarro, Maria Victoria
A1 De-Alarcon, Aristides
K1 Enterococcus faecalis
K1 Ampicillin
K1 Ceftriaxone
K1 Infective endocarditis
K1 Outpatient parenteral antibiotic treatment
AB Ampicillin plus ceftriaxone (AC) is a well-recognized inpatient regimen for Enterococcus faecalis infective endocarditis (IE). In this regimen, ceftriaxone is usually administered 2 g every 2 h (AC12). The administration of AC in outpatient parenteral antibiotic treatment (OPAT) programs is challenging because multiple daily doses are required. AC regimens useful for OPAT programs include once-daily high-dose administration of ceftriaxone (AC24) or AC co-diluted and jointly administered in bolus every 4 h (ACjoined). In this retrospective analysis of prospectively collected cases, we aimed to assess the clinical effectivity and safety of three AC regimens for the treatment of E. faecalis IE. Fifty-nine patients were treated with AC combinations (AC12 n = 32, AC24 n = 17, and ACjoined n = 10). Six relapses occurred in the whole cohort: five (29.4%) treated with AC24 regimen and one (10.0%) with ACjoined. Patients were cured in 30 (93.3%), 16 (94.1%), and eight (80.0%) cases in the AC12, AC24 and ACjoined groups, respectively. Unplanned readmission occurred in eight (25.0%), six (35.3%), and two (20.0%) patients in the AC12, AC24 and ACjoined groups, respectively. The outcome of patients with E. faecalis IE treated with AC in OPAT programs relies on an optimization of the delivery of the combination. AC24 exhibit an unexpected rate of failures, however, ACjoined might be an effective alternative which clinical results should corroborate in further studies.
PB MDPI
SN 2077-0383
YR 2021
FD 2021-12-21
LK http://hdl.handle.net/10668/21221
UL http://hdl.handle.net/10668/21221
LA en
NO Herrera-Hidalgo L, Lomas-Cabezas JM, López-Cortés LE, Luque-Márquez R, López-Cortés LF, Martínez-Marcos FJ, et al. Ampicillin Plus Ceftriaxone Combined Therapy for Enterococcus faecalis Infective Endocarditis in OPAT. J Clin Med. 2021 Dec 21;11(1):7
NO The authors received no financial support for the research, authorship, and/or publication of this article. GVA was supported by the Instituto de Salud Carlos III, cofinanced by the European Regional Development Fund (“A way to achieve Europe”), Subprograma Miguel Servet (grant CP19/00159). HHL was supported by the Instituto de Salud Carlos III, Subprograma Rio Hortega (grant CM19/00152).
DS RISalud
RD Apr 17, 2025